GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LBT Innovations Ltd (ASX:LBT) » Definitions » EV-to-EBITDA

LBT Innovations (ASX:LBT) EV-to-EBITDA : -1.55 (As of Jun. 18, 2024)


View and export this data going back to 2006. Start your Free Trial

What is LBT Innovations EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LBT Innovations's enterprise value is A$25.24 Mil. LBT Innovations's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.33 Mil. Therefore, LBT Innovations's EV-to-EBITDA for today is -1.55.

The historical rank and industry rank for LBT Innovations's EV-to-EBITDA or its related term are showing as below:

ASX:LBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.56   Med: -0.49   Max: 42.75
Current: -1.55

During the past 13 years, the highest EV-to-EBITDA of LBT Innovations was 42.75. The lowest was -35.56. And the median was -0.49.

ASX:LBT's EV-to-EBITDA is ranked worse than
100% of 480 companies
in the Medical Devices & Instruments industry
Industry Median: 15.39 vs ASX:LBT: -1.55

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-18), LBT Innovations's stock price is A$0.017. LBT Innovations's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.044. Therefore, LBT Innovations's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


LBT Innovations EV-to-EBITDA Historical Data

The historical data trend for LBT Innovations's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LBT Innovations EV-to-EBITDA Chart

LBT Innovations Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.07 -10.46 -2.46 -4.62 -0.69

LBT Innovations Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -4.62 - -0.69 -

Competitive Comparison of LBT Innovations's EV-to-EBITDA

For the Medical Devices subindustry, LBT Innovations's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LBT Innovations's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LBT Innovations's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LBT Innovations's EV-to-EBITDA falls into.



LBT Innovations EV-to-EBITDA Calculation

LBT Innovations's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=25.244/-16.327
=-1.55

LBT Innovations's current Enterprise Value is A$25.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LBT Innovations's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-16.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LBT Innovations  (ASX:LBT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

LBT Innovations's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.017/-0.044
=At Loss

LBT Innovations's share price for today is A$0.017.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LBT Innovations's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.044.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


LBT Innovations EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of LBT Innovations's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


LBT Innovations (ASX:LBT) Business Description

Traded in Other Exchanges
N/A
Address
16 Anster Street, Adelaide, SA, AUS, 5000
LBT Innovations Ltd is a designer of advanced technology solutions for the medical industry. Its first product, MicroStreak, was a global first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation.

LBT Innovations (ASX:LBT) Headlines

No Headlines